Skip to main content

Ibrahim Aldoss, MD

Ibrahim Aldoss, MD
Conference Coverage
12/13/2023
At the 65th ASH Annual Meeting, Ibrahim Aldoss, MD, shared phase 2 results on the value of revumenib monotherapy among patients with heavily pretreated, relapsed/refractory KMT2Ar acute leukemia.
At the 65th ASH Annual Meeting, Ibrahim Aldoss, MD, shared phase 2 results on the value of revumenib monotherapy among patients with heavily pretreated, relapsed/refractory KMT2Ar acute leukemia.
At the 65th ASH Annual Meeting,...
12/13/2023
Oncology